Securities code: Honz Pharmaceutical Co.Ltd(300086) securities abbreviation: Honz Pharmaceutical Co.Ltd(300086) Announcement No.: 2022016
Honz Pharmaceutical Co.Ltd(300086)
Financial statement report of 2021
In order to enable all directors to fully understand the company’s financial situation and operating results in 2021, the relevant information of the financial statements in 2021 is reported as follows:
1、 Basic information
The final financial statements of the company include the balance sheet, income statement, cash flow statement, statement of changes in owner’s equity and notes to the accounting statements as of December 31, 2021, which were audited by China audit Zhonghuan Certified Public Accountants (special general partnership), and China audit Zhonghuan Certified Public Accountants (special general partnership) issued a standard audit report for the company. Audit opinion: in our opinion, the financial statements of Honz Pharmaceutical Co.Ltd(300086) are prepared in accordance with the accounting standards for business enterprises in all major aspects, and fairly reflect the financial situation of Honz Pharmaceutical Co.Ltd(300086) as of December 31, 2021 and the operating results and cash flow of Honz Pharmaceutical Co.Ltd(300086) as well as the parent company in 2021.
At the end of 2021, the total assets of the company were 245878165413 yuan, the total liabilities were 90513978935 yuan, and the owner’s equity was 155364186478 yuan (including 150394921927 yuan of owner’s equity attributable to the parent company); The annual operating income was 83656580556 yuan, the total profit was 2035436372 yuan, and the net profit was 1057141791 yuan (the net profit attributable to the parent company was 1098750499 yuan).
2、 Financial status and operating results during the reporting period
1. Asset liability structure
At the end of 2021, the total assets of the company were 245878165413 yuan, a decrease of – 5.93% over the same period of last year; The total current liabilities amounted to RMB 21951943%, accounting for 29904343% of the total liabilities in the same period of the previous year, accounting for 29904343% of the total liabilities of the previous year, accounting for 2951943%; The asset liability ratio was 36.81%, down 1.90% over the same period last year; The current ratio was 1.48, an increase of 0.26 over the same period last year; The quick ratio was 1.08, an increase of 0.22 over the same period last year.
2. Economic benefit status and analysis
In 2021, the annual operating income was 836580556 yuan, a decrease of 9.23%; The total profit was 2035436372 yuan, a decrease of 840601391 yuan over the previous year, with a decrease rate of 29.23%; The annual comprehensive gross profit margin was 50.46%, 51.30% in the same period last year, a decrease of 0.85% over the same period last year; All kinds of taxes actually paid in the whole year were 6245861363 yuan, accounting for 7.47% of the operating revenue, an increase of 1867087990 yuan or 42.64% over the previous year. The net profit attributable to the shareholders of the parent company was 1098750499 yuan, compared with 933925211 yuan in the same period last year, with a year-on-year increase of 17.65%.
3. Cost status
In 2021, the operating cost of the company was 41446032490 yuan, a decrease of 3434569596 yuan or 7.65% over the previous year, accounting for 49.54% of the operating revenue, and the revenue cost ratio increased by 0.85% over the previous year; The sales expense was 28647138267 yuan, an increase of 11.34% over the previous year, accounting for 34.24% of the operating revenue, and the ratio of revenue to sales expense increased by 6.33% year-on-year; The management expense was 9755848621 yuan, a decrease of 11.63% over the previous year, accounting for 11.66% of the operating revenue, and the ratio of revenue and management expense decreased by 0.32% year-on-year.
4. Cash flow
In 2021, the net cash flow from the company’s operating activities was 1132933682 yuan, an increase of 2807216653 yuan over the previous period, with a growth rate of 167.67%. The net cash flow from investment activities was 9091539043 yuan and the net cash flow from financing activities was -10960960825 yuan. By the end of 2021, the company’s monetary capital balance was 25855326195 yuan, an increase of 28354982 yuan over the same period last year.
2、 Asset status and operation analysis
1. Asset status analysis
As of December 31, 2021, the total assets of the company were 245878165413 yuan: the total current assets were 71989951227 yuan, accounting for 29.28% of the total assets, an increase of 1092423287 yuan over the same period of the previous year, with a growth rate of 1.54%; The net fixed assets was 330 Ikd Co.Ltd(600933) 31 yuan, accounting for 13.45% of the total assets, a decrease of 116115390 yuan or 0.35% over the same period last year; The construction in progress was 65927612942 yuan, accounting for 26.81% of the total assets, an increase of 8680934149 yuan over the same period last year, with a growth rate of 15.16%; The net amount of intangible assets was 20268028426 yuan, accounting for 8.24% of the total assets, an increase of 3895094202 yuan over the same period last year, with an increase rate of 23.79%; Goodwill is 1889196366 yuan, accounting for 0.77% of the total assets.
2. Other main indicators are as follows:
(1) The share capital was 450 million shares at the end of the year.
(2) The capital reserve at the end of the year was 81896049679 yuan, a decrease of 97594007 yuan over the same period of the previous year
(3) The surplus reserve at the end of the year was 5282648728 yuan.
(4) The undistributed profit at the end of the year was 12951109414 yuan, and the undistributed profit at the end of the previous year was 13266976531 yuan, a decrease of 315867117 yuan over the previous year.
4、 Main financial indicators
1. The basic earnings per share was 0.0244 yuan / share, compared with 0.0208 yuan / share in the same period last year, an increase of 0.0036 yuan per share over last year, an increase of 17.31%.
2. The weighted average return on net assets was 0.73%, 0.62% in the same period last year, an increase of 0.11% over the previous year; The weighted average return on net assets (after deduction of non-performing assets) – 2.72%, 1.38% in the same period last year, a decrease of 4.10% over the previous year.
Honz Pharmaceutical Co.Ltd(300086)
Board of directors
April 6, 2022
